Fouts T R, Tuskan R, Godfrey K, Reitz M, Hone D, Lewis G K, DeVico A L
Institute of Human Virology, University of Maryland Biotechnology Institute, University of Maryland, Baltimore, Maryland 21201, USA.
J Virol. 2000 Dec;74(24):11427-36. doi: 10.1128/jvi.74.24.11427-11436.2000.
The infection of CD4(+) host cells by human immunodeficiency virus type 1 (HIV-1) is initiated by a temporal progression of interactions between specific cell surface receptors and the viral envelope protein, gp120. These interactions produce a number of intermediate structures with distinct conformational, functional, and antigenic features that may provide important targets for therapeutic and vaccination strategies against HIV infection. One such intermediate, the gp120-CD4 complex, arises from the interaction of gp120 with the CD4 receptor and enables interactions with specific coreceptors needed for viral entry. gp120-CD4 complexes are thus promising targets for anti-HIV vaccines and therapies. The development of such strategies would be greatly facilitated by a means to produce the gp120-CD4 complexes in a wide variety of contexts. Accordingly, we have developed single-chain polypeptide analogues that accurately replicate structural, functional, and antigenic features of the gp120-CD4 complex. One analogue (FLSC) consists of full-length HIV-1BaL gp120 and the D1D2 domains of CD4 joined by a 20-amino-acid linker. The second analogue (TcSC) contains a truncated form of the gp120 lacking portions of the C1, C5, V1, and V2 domains. Both molecules exhibited increased exposure of epitopes in the gp120 coreceptor-binding site but did not present epitopes of either gp120 or CD4 responsible for complex formation. Further, the FLSC and TcSC analogues bound specifically to CCR5 (R5) and blocked R5 virus infection. Thus, these single-chain chimeric molecules represent the first generation of soluble recombinant proteins that mimic the gp120-CD4 complex intermediate that arises during HIV replication.
1型人类免疫缺陷病毒(HIV-1)对CD4(+)宿主细胞的感染始于特定细胞表面受体与病毒包膜蛋白gp120之间一系列相互作用的时间进程。这些相互作用产生了许多具有不同构象、功能和抗原特性的中间结构,这些结构可能为抗HIV感染的治疗和疫苗策略提供重要靶点。其中一种中间结构,即gp120-CD4复合物,是由gp120与CD4受体相互作用产生的,它能够与病毒进入所需的特定共受体相互作用。因此,gp120-CD4复合物是抗HIV疫苗和治疗的有希望的靶点。在多种情况下生产gp120-CD4复合物的方法将极大地促进此类策略的发展。因此,我们开发了单链多肽类似物,它们能准确复制gp120-CD4复合物的结构、功能和抗原特性。一种类似物(FLSC)由全长HIV-1BaL gp120和CD4的D1D2结构域通过一个20个氨基酸的接头连接而成。第二种类似物(TcSC)包含一种截短形式的gp120,缺少C1、C5、V1和V2结构域的部分。两种分子在gp120共受体结合位点的表位暴露均增加,但未呈现负责复合物形成的gp120或CD4的表位。此外,FLSC和TcSC类似物特异性结合CCR5(R5)并阻断R5病毒感染。因此,这些单链嵌合分子代表了第一代可溶性重组蛋白,它们模拟了HIV复制过程中出现的gp120-CD4复合物中间体。